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Abstract
Immunohistochemistry is one of the most suitable methods for the detection of intratumoral aromatase in order to identify
patients who may respond to aromatase inhibitor therapy in hormone-dependent breast cancer. Previous studies showed
statistically significant correlation between results of immnuohistochemistry and biochemical analysis in carcinoma
components stained by aromatase monoclonal antibody 677. In this study, determination of the antigenic peptides
recognized by aromatase antibodies through epitope mapping, combined with the new knowledge on aromatase-
reductase interaction, provide insights for understanding various immunostaining patterns using different aromatase
antibodies. Our studies on aromatase-reductase interaction also provided critical information on how aromatase and
reductase interact with each other on the endoplasmic reticulum membrane, and identified key residues, including K108 of
aromatase, that are involved in the interaction with reductase. Through epitope mapping and taking into consideration the
interference with aromatase immunohistochemical staining by NADPH-cytochrome P450 reductase, we demonstrated that
monoclonal antibody 677 is a suitable antibody for an assessment of intratumoral aromatase activity in breast cancer
patients for making clinical management decisions. These results also provide valuable information to identify new
aromatase antibodies for immunohistochemical diagnosis of hormone-dependent breast cancer in future.
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Introduction
Aromatase is the rate-limiting enzyme in estrogen biosynthesis.
Estrogen plays an important role in breast cancer development.
Upon binding to estrogen, estrogen receptor activates transcrip-
tion of its target genes, which are responsible for cancer cell
proliferation in hormone-dependent breast tumors. Increased
aromatase expression and activity have been reported in human
breast tumor compared with normal breast tissue [1–3].
Intratumoral aromatase is a therapeutic target for the treatment
of hormone-dependent breast cancer in post-menopausal women.
Immunohistochemistry is one of the most suitable methods for the
detection of intratumoral aromatase. Some studies have demon-
strated the correlation between the response to aromatase
inhibitor therapy and the amount of intratumoral aromatase
activity or expression [4,5]. Therefore, reliable aromatase
antibodies for immunohistochemistry are of help in the charac-
terization of hormone-dependent breast cancer in order to
potentially identify post-menopausal patients with ER positive
tumors who will respond to aromatase inhibitor therapy.
Several antibodies [1,6–9] have been used to detect aromatase by
immunohistochemistry but all of them are associated with the
following limitations: (1) insufficient characterization of antibodies,
(2) aromatase immnunoreactivity was evaluated by only one
pathologist, (3) aromatase immunoreactivity in tissue sections were
not scored or graded, (4) no correlations were examined between
aromatase immunoreactivity and intratumoral aromatase activity
[10]. Therefore, a multi-centre collaborative group has been
established to generate and validate new aromatase monoclonal
antibodies using purified recombinant GST-aromatase fusion
protein as antigen for immunization of mice [11]. Their objective
was to produce specific monoclonal antibodies (MCAs) against
aromatase that are capable of detecting aromatase through
immunohistochemistry of 10% formalin-fixed paraffin embedded
sections of breast carcinomas and establishment of scoring systems
which would be best correlated with biochemical assays of the same
specimens. Twenty-three MCAs selected by biochemical assays
were evaluated by immunohistochemistry of paraffin-embedded
tissue sections including normal ovary and placenta, and a small
series of 10 breast carcinomas. Further definitive characterization
using 43 cases of breast cancer showed statistically significant
correlation between results of immnuohistochemistry and biochem-
ical analysis in carcinoma components stained by MCA 677, an
antibody against native aromatase protein. Therefore, MCA 677
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e8050could be used in quantitative assessment of intratumoral aromatase
activity in breast cancer patients for making clinical management
decisions.To explain why MCA 677 is a betterantibody, an epitope
mapping is essential for a precise determination of which area of
aromatase protein recognized by this antibody.
At present, aromatase antibodies have been engineered mainly
against aromatase protein without the consideration of the interference
of reductase in vivo. Aromatase belongs to the cytochrome P450 family,
and forms an electron-transfer complex with its partner, NADPH-
cytochrome P450 reductase, during the aromatization of androgen to
estrogen. Reductase is composed of four domains: the FMN-binding
domain, connecting domain, FAD-binding domain, and the NADP-
binding domain, revealed by the crystal structure of reductase solved in
1997 [12]. During the aromatization reaction, electrons are transferred
from NADPH, through FAD and FMN, to the heme of aromatase.
The membrane binding site of reductase is situated around the V64
residue and near some hydrophobic patches of the surface, most likely,
containing loops 250–281, 516–525, and 553–557 [12]. These
membrane binding sites enable reductase to sit on the endoplasmic
reticulum membrane, thus reductase adopts an orientation in which
the FMN, FAD, and NADP binding sites are facing towards the
cytoplasmic side. The crystal structure of human aromatase, solved
recently by Ghosh and co-workers, represents a major breakthrough in
aromatase research [13]. In their proposed membrane integration
m o d e l ,t h eo p e n i n gt ot h ea c t i v es i t ea c c e s sc h a n n e lr e s t so nt h el i p i d
bilayer of endoplasmic reticulum, allowing the steroidal substrate to
enter into the active site directly from the bilayer. This model suggests
that lipid integration/association sites include the N terminus up to the
A helix and other loops near the C terminus [13]. A number of studies
indicate the interactions between cytochrome P450 enzymes and
reductase comprise interaction of the hydrophobic membrane binding
portions and electrostatic attraction [14–17]. However, the molecular
basis for the interaction between aromatase and reductase in vivo is not
yet fully understood. In this study, determination of the antigenic
peptides recognized by aromatase antibodies through epitope
mapping, combined with the new knowledge on aromatase-reductase
interaction, provide insights for understanding various immunostaining
patterns using different aromatase antibodies.
Results
Immunohistochemical Analysis of Aromatase
Two MCAs 677 and F11 were used in this study. These two
MCAs were generated and validated by a multi-centre collabo-
rative group [10,11] using recombinant baculovirus-expressed
human aromatase protein as antigen; MCA 677 was raised against
native protein and F11 against formalin-fixed protein. These two
monoclonal antibodies could demonstrate aromatase immunore-
activity in breast cancer tissue specimens. Representative immu-
nohistochemistry staining of human breast cancer specimens using
these two MCAs is shown in Fig. 1. Furthermore, immunohisto-
chemical staining results showed that a significant positive
correlation was detected between aromatase immunohistochem-
istry stained with MCA 677 and aromatase biochemical activity in
human breast carcinoma tissue specimens, while staining using
MCA F11 as a primary antibody did not produce a positive
correlation with aromatase activity (data not shown).
Aromatase Epitope Analysis
TounderstandwhyMCA677 isabetterantibodythan MCAF11
in the detection of aromatase in breast cancer tissues, we identified
their peptide antigens through epitope mapping. One additional
MCA,2077, and one polyclonalantiserum were also included inthis
study. MCA 2077 was used as a reference control since it was raised
using a peptide antigen–KALEDDVIDGYPVKKC, corresponding
to amino acids 376–390 of human aromatase, plus an extra C-
terminal cysteine residue [18]. The polyclonal antiserum was
generated againstfunctionallyactive human recombinantaromatase
produced by the Chen laboratory [26].
Pure human recombinant aromatase protein was subjected to
digestion by trypsin, and digested peptides were separated by
reversed-phase HPLC using a PROTEO C18 HPLC column
(Fig. 2). HPLC fractions were applied for ELISA using MCAs 677,
F11, and 2077, and antiserum (Fig. 3). ELISA-positive fractions
were analyzed by linear quadrupole ion trap Fourier transform
mass spectrometer (LTQ-FT-MS) to identify the peptides in those
fractions (Fig. 4). MCA 2077 recognized fractions 24 and 25.
Fraction 24 contained the antigenic peptide–amino acids 376–390
of human aromatase, and fraction 25 contained the same peptide
without an N-terminal lysine residue. MCA F11 recognized the
same fractions as MCA 2077. MCA 677 recognized fractions 45
and 46, and these two fractions contained a same peptide–
DLKDAIEVLIAEK, corresponding to amino acids 250–262 of
human aromatase. The same peptide was also recognized by the
antiserum generated in our laboratory. Besides this one, antiserum
also recognized fraction 22, and it contained peptide–
IHDLSLHPDETK, corresponding to amino acids 474–485 of
human aromatase. We didn’t find any peptides in faction 13,
which was positive by ELISA assay using the antiserum. These
epitopes are located on the surface of aromatase protein.
Electrostatic Interaction between Aromatase and
Reductase
To determine whether the interference of reductase contributes
to different immunohistochemistry staining using MCAs #677
Figure 1. Immunohistochemical detection of aromatase in human breast carcinoma tissue specimens. (A) MCA 677; (B) F11.
doi:10.1371/journal.pone.0008050.g001
Aromatase Epitope Mapping
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reductase. Previous studies suggest the interactions between
reductase and cytochrome P450 enzyme comprise interaction of
the hydrophobic membrane binding portions and electrostatic
attraction [14–17]. Multiple sequence alignments of cytochrome
P450s have shown that there are five homologous positions of
positively charged amino acids which have been identified by
protein modification or site-directed mutagenesis as being involved
in the interaction with reductase [19–22]. In human aromatase,
these candidate residues are K99, K108, K389/K390, K420, and
R425 through sequence alignments with cytochrome P450 1A1,
1A2, 2B1, and 2B4. To check for potential electrostatic interaction
between aromatase and reductase, we calculated the surface
electrostatic potential of the crystal structures of aromatase (PDB:
3EQM) and reductase (PDB: 1AMO) by PYMOL. Surface
electrostatic potential maps confirm that the FMN domain of
reductase is mainly negatively charged and the surface of the heme
proximal side of aromatase is highly positively charged. This
agrees with the hypothesis that the FMN-binding domain of
reductase provides a major surface for the electrostatic interaction
with aromatase, since electrons exit from the FMN-binding
domain and transfer to the heme of aromatase. This model also
agrees with the assumption that the heme proximal side of
aromatase faces reductase based on the fact that substrate binds to
the heme distal side of aromatase.
Computer Modeling Analysis of the Interaction between
Aromatase and Reductase
To better understand how aromatase interacts with reductase, we
performed computer-assisted molecular docking. Direct rigid
docking of the crystal structure of aromatase into the crystal
structure of reductase using ZDOCK suggested that reductase may
adopt a structural rearrangement when it forms the complex with
aromatase. Flexible step-wise docking approach was then applied.
Firstly, aromatase was docked with the FMN domain of reductase.
The FAD and NADP domains were then docked into the complex.
Protein-protein docking decoys were produced from ZDOCK [23]
software version 3.0.1. A total of 13500 decoys were generated by
selecting dense rotational sampling. The docking scores were then
re-calculated based on the consensus of four equally-weighted
measurements including: 1. distance between the FMN of reductase
and the heme of aromatase; 2. whether the proximal surface of
aromatase interacts with reductase; 3. whether aromatase forms ion
pairs with reductase through predictive residues K99, K108, K389/
K390, K420, or R425; 4. angle of two planes determined by the
membranebindingsurfaces of reductase and aromatase. The model
with the highest docking score is shown in Fig. 5.
This docking model allows the N-terminal transmembrane
domains and the membrane binding portions of two proteins to
face the same orientation. The distance between the N5 atom of
FMN and the heme iron is 18.8 A ˚, which is similar to the distance
in the crystal structure of P450BM3, a self-sufficient enzyme with
the heme domain and the reductase domain linked together on a
single polypeptide [24]. It also allows electrostatic interactions
between K108 of aromatase and N175/T177 of reductase and
between K420 of aromatase and E115 of reductase. Residues
N175, T177, and E115 of reductase are located within two
important peptides, 175–182 and 109–130. Peptide 175–182 of
reductase was predicted to be involved in the interaction between
cytochrome c and reductase [12]. Carboxylate residues within the
peptide 109–130 of reductase were identified as involved in the
interaction with cytochrome P450 PB-b using radiolabelled
nucleophile followed by proteolysis of the labeled protein [25].
Validation of the Docking Model
Computer-assisted model predicts electrostatic interaction
between residues N175/T177 of reductase and residue K108 of
aromatase. Residue K108 is located at the edge of the B’ helix
(S
100SSMFHIMK
108) of aromatase. The B’ helix is situated on the
proximal surface of aromatase, and intrudes into the cleft between
the FMN and FAD domains of reductase in the docking model,
enabling K108 of aromatase to interact with N175/T177 of
reductase. The amino acid sequence of the B’ helix is well
conserved among the aromatase family (Fig. 6A). To validate the
predicted function of the K108 residue, we generated the K108Q
mutant using site-directed mutagenesis. Aromatase activity assay
using transfected CHO cells showed that aromatase activity of the
K108Q mutant was significantly decreased (Fig. 6B). Western blot
Figure 2. Reverse-phase HPLC tryptic peptide map of human recombinant aromatase. The dashed line represents CH3CN gradients.
doi:10.1371/journal.pone.0008050.g002
Aromatase Epitope Mapping
PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e8050by polyclonal aromatase antibody confirmed that the mutant
protein level is similar to the WT aromatase in transfected CHO
cells (Fig. 6C).
In our laboratory, we have developed an experimental
procedure to purify catalytically active recombinant aromatase
[26]. We also express and purify full-length NADPH-cytochrome
Figure 3. Peptide ELISA with four different aromatase antibodies.
doi:10.1371/journal.pone.0008050.g003
Aromatase Epitope Mapping
PLoS ONE | www.plosone.org 4 November 2009 | Volume 4 | Issue 11 | e8050Figure4.PeptideanalysisusingLTQ-FTmassspectrometer.(A)MSandMS/MSofHPLCfraction25thatwasrecognizedbyMCAs2077andF11.The
insetisthefragmentation(MS/MS)spectrumofthedominantpeptideatm/z781[MH2(2+)]. These experimental MS/MS fragment ions matchto theoretical
fragmentionsproducedbypeptideALEDDVIDGYPVKK,correspondingtoaminoacids377–390ofhumanaromatase.(B)MSandMS/MSofHPLCfraction46
thatwasrecognizedbyMCA677.Theinsetisthefragmentation(MS/MS)spectrumofthedominantpeptideatm/z729[MH2(2+)]. These experimentalMS/
MS fragment ions match to theoretical fragment ions produced by peptide DLKDAIEVLIAEK, corresponding to amino acids 250–262 of human aromatase.
doi:10.1371/journal.pone.0008050.g004
Aromatase Epitope Mapping
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[27]. To further determine whether the K108 residue is indeed
involved in the interaction with reductase, we expressed and
purified mutant protein from E. coli according to a procedure
previously described [26]. The K108Q mutant showed a substrate
binding spectrum in the presence of androstenedione, demon-
strating that the K108Q mutation doesn’t affect the substrate
binding property of aromatase (Fig. 6D). Enzyme kinetic analysis
using pure enzyme preparations were performed to determine the
androgen substrate and reductase binding properties of the
K108Q mutant. Aromatase activity in converting androstenedione
to estrone or oxidizing reductase was measured by the release of
tritiated water from [1b-
3H(N)]-androstenedione. The Km (Mi-
chaelis-Menten constant) values of aromatase for androstenedione
and reductase were estimated to be 200 nM and 1 nM from the
Lineweaver–Burk plots (Figs. 7A & B). The Km values of the
K108Q mutant for androstenedione and reductase were estimated
to be 200 nM and 20 nM from Lineweaver–Burk plots (Figs. 7C &
D). Although Km is not a dissociation constant that measures the
binding strength, it can be used as an indicator of binding affinity.
The K108Q mutation didn’t change the binding affinity of the
androgen substrate, however, it dramatically deceased the binding
affinity of reductase. The aromatase-reductase interaction is highly
sensitive to the modification of a surface basic residue K108, which
supports a strong dependence on electrostatic interaction.
Discussion
Both 677 and F11 reacted with aromatase by western blot, and
gave specific cytoplasmic staining of epithelial cancer cells and
minimal background staining [11]. However, a significant positive
correlation between immunohistochemistry and aromatase bio-
chemical activity was detected only in malignant epithelium
stained with 677. Epitope mapping demonstrated MCA 677
recognized amino acids 250–262 of human aromatase, which are
exposed in the cytoplasm, while MCA F11 recognized amino acids
376–390 of human aromatase, which are near the endoplasmic
reticulum membrane and are covered by reductase from the
docking model presented in this study (Fig. 5). It is likely that
reductase interferes with the binding of MCA F11 to its epitope on
Figure 5. Computer-assisted docking model of the aromatase-reductase complex. A ribbon representation of the aromatase (blue)-
reductase (green) complex showing its association with endoplasmic reticulum membrane (purple). The docking model was produced from ZDOCK
[23] software version 3.0.1. NADP, FAD, FMN, HEME, and androstenedione are shown in stick representation, and colored in orange, blue, purple, red,
and yellow, respectively. The distance between the N5 atom of FMN and the heme iron is 18.8 A ˚. Residues K108 and K420 of aromatase are colored in
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MCA 677 is away from the reductase binding site and the
androgen access channel (predicted by Dr. Ghosh from the crystal
structure of aromatase), thus MCA 677 is a good immunohisto-
chemical antibody. However, MCA 677 would not be suitable for
studies involving inhibition of the aromatase enzyme activity and
this has been confirmed in our own studies (unpublished results).
Epitope mapping combined with the knowledge on the binding
orientation of reductase in the predictive aromatase-reductase
complex provide insights into understanding why MCA 677 is a
good antibody in the detection of aromatase in breast cancer
tissues. These results also provide valuable information to identify
new aromatase antibodies for immunohistochemistry in order to
characterize hormone-dependent breast cancer in future.
Computer-assisted docking, combined with biochemical exper-
iments including site-directed mutagenesis and kinetic analysis, led
us to propose an aromatase-reductase complex model, and reveal
that the FMN domain of reductase undergoes a structural
rearrangement, allowing the proximal surface of aromatase to fit
in the cleft between the FNN and FAD domains of reductase.
Recently, crystal structures of a reductase variant with a four
amino acid deletion in the hinge connecting the FMN and FAD
domains reveal the FMN domain of reductase undergoes a
structural rearrangement that separates it from the FAD domain
and exposes the FMN domain, allowing it to interact with its redox
partner, cytochrome P450 [28]. Hamdane and co-workers
proposed that a similar movement occurs in the wild type enzyme
in the course of transferring electrons from FMN to cytochrome
P450, which has been hypothesized elsewhere [12,24,29]. We also
identified key residues including K108 on the surface of aromatase
that are involved in the interaction with reductase. The results
from immunohistochemical staining, on the other hand, support
our prediction for the aromatase-reductase binding model.
Without a crystal structure of the aromatase-reductase complex,
our studies provide critical information on how aromatase and
reductase interact with each other on the endoplasmic reticulum
membrane.
In conclusion, Aromatase inhibitor therapy is one of the
hormonal treatments available to postmenopausal breast cancer
patients. It has become important to identify patients who may
respond to aromatase inhibitor therapy before it is initiated. The
measurement of intratumoral aromatase content might provide
parameters of response to aromatase inhibitors in addition to
estrogen receptor measurement in surgical pathology specimens.
In this study, determination of the antigenic peptides recognized
by current aromatase antibodies through epitope mapping, and
taking into consideration of the interference with aromatase
immunohistochemical staining by reductase, we demonstrated that
Figure 6. Validation of predicted function of residue lysine-108. (A) Amino acid sequences alignment of the B’ helix of the aromatase family.
(B) Aromatase activity assay of WT aromatase and the K108Q mutant in CHO cells. (C) Western blot analysis on whole-cell lysates from CHO cells
control or transfected with WT or K108Q aromatase using aromatase polyclonal antibody. (D) Substrate binding spectrum of the K108Q aromatase in
the presence of androstenedione.
doi:10.1371/journal.pone.0008050.g006
Aromatase Epitope Mapping
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Immunohistochemical analyses were principally performed
employing the streptavidin-biotin amplification method, and have
been previously described in detail [10,11].
Trypsin Digestion
Two milligram of pure human recombinant aromatase were
concentrated into a thick, jelly-like mess using vacuum drying,
then dissolved in 225 ml of 8 M deionized Urea solution plus 25 ml
of 1 M NH4HCO3. The mixture was incubated at 56uC for 15
minutes after adding 25 ml of 45 mM DTT, followed by
incubation at room temperature for another 15 minutes in the
dark after adding 25 ml of 100 mM Iodoacetamide. Add 75 mlo f
1MN H 4HCO3 to the solution, and dilute it with MilliQ-water to
a final volume of 1 ml. Add 40 ml1mg/ml trypsin stock to give a
1:50 trypsin:protein ratio by mass, and incubate overnight at
30uC. Quench the reaction with 50 ml of ultra-pure glacial acetic
acid. Centrifuge the sample at 14,000 rpm for 10 minutes to
remove the pellet, then store frozen until analyzed.
Peptide Separation
Trypsin-digested aromatase peptides were separated by reversed-
phase high-pressure liquid chromatography (HPLC) using a
PROTEO C18 HPLC column (the Nest Group, Inc.). 50 mlo f
peptides mixture was loaded onto the column each time, and eluted
with a step gradient of CH3CN (Buffer A=0.1% TFA in H2O;
BufferB=0.1%TFAin10% H2O, 90% CH3CN;2%B for6 min,
2% B to 10% B for 3 min, 10% B to 35% B for 42 min, 35% B to
50% B for 4 min, 50% B to 95% B for 2 min, 95% B for 6 min,
95% B to 2% B for 3 min, and 2% B for 5 min). A total of 51
fractions were collected according to the absorbance at 214 nm.
Enzyme-Linked Immunosorbent Assay (ELISA)
HPLC fractions were dried using vacuum drying, then dissolved
in 205 ml 50 mM NaHCO3 buffer, pH 9.0. Fifty micromole of the
each sample were added into a 96-well ELISA plate. After the
incubation at 4uC overnight, remove antigen, add 400 ml blocking
buffer (PBS +1% BSA +0.02% azide), and incubate the plate at
room temperature for 2 hours. Remove the blocking buffer, wash
once with 200 ml PBS plus 0.02% azide, add 50 ml antibody
diluted in blocking buffer (MCA 677=1:200, MCA F11=1:200,
MCA 2077=1:200, antiserum=1:500), and incubate the plate at
room temperature for 1.5 hours. Remove the antibody solution,
wash three times with 200 ml PBS plus 0.05% Tween-20, add
50 ml anti-mouse or anti-rabbit HRP conjugated secondary
antibody with 1:1000 dilution in blocking buffer, and incubate
the plate at room temperature for 1.5 hours. Remove the
secondary antibody solution, wash three times with 200 ml PBS
plus 0.05% Tween-20, add 50 ml DY999 substrate (R&D systems,
Inc.), incubate the plate at room temperature for 20 min, add
50 ml 5.7% H2SO4, mix, then read OD at 450 nm using
SpectraMax M5 plate reader (Molecular Devices).
Figure 7. Lineweaver–Burk plots of aromatase kinetic analysis. (A) and (C). Kinetic analysis of recombinant aromatase or the K108Q mutant
with substrate androstenedione (from 10 nM to 500 nM) in the presence of reductase (from 2 nM to 20 nM). (B) and (D). Kinetic analysis of
recombinant aromatase or the K108Q mutant with substrate reductase (from 1 nM to 20 nM) in the presence of androstenedione (from 10 nM to
500 nM). Aromatase activity assay were performed by the tritiated water release method using [1b-
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Absorption spectrum of aromatase-androstenedione was mea-
sured by a UV-1700 PharmaSpec UV-Vis Spectrophotometer
(Shimadzu Scientific Instruments, Columbia, MD) with a 1-cm
quartz cuvette. Buffer containing 50 mM potassium phosphate
(pH 7.4) and 20% glycerol was used as spectral reference. Sample
contained 0.1 mg/ml pure K108Q mutant protein with 2 mM
androstenedione in reference buffer.
Kinetic Analysis of Aromatase
Aromatase activity was measured by the release of tritiated
water from [1b-
3H(N)]-androstenedione. In vitro aromatase activity
assay was reconstituted with 50 nM pure human recombinant
aromatase in a 200-mL reaction solution containing 67 nM
potassium phosphate (pH 7.4), 0.1% BSA, 10 mM progesterone,
pure rat reductase, and [1b-
3H(N)]-androstenedione at 37uC for
20 min. The concentration of pure rat reductase ranged from
1 nM to 20 nM. The concentration of [1b-
3H(N)]-androstenedi-
one was ranged from 10 nM to 500 nM. The incubation was
initiated by the addition of 300 mM NADPH, and terminated by
the addition of 50 ml 20% trichloroacetic acid. The reaction
solution was mixed with charcoal-dextran to remove any trace
amount of unreacted substrate. After centrifugation, the radioac-
tivity of the supernatant was counted by a liquid scintillation
counter (LS 6500; Beckman Coulter, Inc., Fullerton, CA). The Km
and Vmax values of aromatase were determined from Lineweaver–
Burk plots. Each point represents the mean of triplicate
experiments.
Site-Directed Mutagenesis
Aromatase mutants were generated by the QuikChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA) using WT
aromatase expression plasmids pHb-Aro [30] or pET3b-Aro [26]
as template. All mutations were verified by DNA sequencing. For
stable cell transfection, mutant pHb-Aro plasmid was transfected
into Chinese Hamster Ovary (CHO) cells using lipofectamine
2000 reagent (Invitrogen, Carlsbad, CA). After two weeks of G418
selection, transfected cells were maintained in media containing
1 mg/ml G418. For protein expression, mutant pET3b-Aro
plasmid was transformed into BL21 (DE3) E. coli strain.
In-Cell Aromatase Activity Assay
In the in-cell aromatase assay, aromatase-transfected CHO cells
were seeded in six-well plates, and 1 mL serum-free media
containing 100 nM [1b-
3H(N)]-androstenedione was added to
each well. After one hour of incubation at 37uC, the media were
mixed with charcoal-dextran to remove any trace amount of
unreacted substrate. After centrifugation, the radioactivity of the
supernatant was counted by a liquid scintillation counter. To
determine protein concentration, cells remaining in each well were
solubilized with 0.5 M NaOH and subjected to the Brad-ford
assay method.
Western Blotting
Aromatase-transfected CHO cells were cultured in 60-mm
dishes and lysed in 300-mL SDS lysis buffer containing
62.5 mmol/L Tris-HCl (pH 6.8), 2% w/v SDS, 10% glycerol,
50 mmol/L DTT, and 0.01% bromophenol blue. Sixty micro-
grams of lysate were resolved on a 10% SDS-PAGE gel and then
transferred onto a polyvinylidene difluoride membrane (Millipore).
The membrane was blocked in a blocking buffer (5% w/v nonfat
dry milk in TBST) for 1 hour at room temperature, incubated
with aromatase antiserum at 1:500 dilution at 4uC overnight, then
incubated with mouse anti-rabbit horseradish peroxidase conju-
gated secondary antibody at 1:5000 dilution (Santa Cruz
Biotechnology) for 1 hour.
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